Skip to main content
Clinical Trials/JPRN-UMIN000010807
JPRN-UMIN000010807
Recruiting
未知

A study on the effect of improving the QOL (quality of life), response and safety of eribulin mesylate for inoperable or recurrent breast cancer - A Study on QOL, response and safety of eribulin for inoperable or recurrent breast cancer

Department of Breast Surgery, Nippon Medical School0 sites100 target enrollmentMay 26, 2013

Overview

Phase
未知
Intervention
Not specified
Conditions
inoperable or recurrent breast cancer
Sponsor
Department of Breast Surgery, Nippon Medical School
Enrollment
100
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 26, 2013
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Breast Surgery, Nippon Medical School

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • \- patients with advanced bone marrow suppression. \- patients who has an anamnesis of hypersensitivity to the ingredient of this agent. \- pregnant women or the women that may have become pregnant \- patients simultaneously treatmented by trastuzumab or lapatinib. \- patients who judged that it was unsuitable as other candidates

Outcomes

Primary Outcomes

Not specified

Similar Trials